| Primary |
| Acute Lymphocytic Leukaemia |
100.0% |
|
| Drug Hypersensitivity |
100.0% |
|
| Secondary |
| Product Used For Unknown Indication |
43.9% |
| Acute Lymphocytic Leukaemia |
36.9% |
| Precursor T-lymphoblastic Lymphoma/leukaemia |
5.6% |
| Acute Myeloid Leukaemia |
2.7% |
| Precursor B-lymphoblastic Lymphoma |
2.1% |
| Lymphoma |
1.5% |
| Prophylaxis |
1.1% |
| T-cell Lymphoma |
0.9% |
| T-cell Type Acute Leukaemia |
0.9% |
| Non-hodgkin's Lymphoma |
0.6% |
| Lymphocytic Leukaemia |
0.6% |
| Antiemetic Supportive Care |
0.5% |
| Acute Lymphoblastic Leukemia |
0.4% |
| Acute Lymphocytic Leukaemia Recurrent |
0.4% |
| B-cell Type Acute Leukaemia |
0.4% |
| Premedication |
0.4% |
| Asthma |
0.3% |
| Hypertension |
0.3% |
| Aplasia |
0.2% |
| Leukaemia |
0.2% |
|
| Venoocclusive Liver Disease |
19.3% |
| Febrile Bone Marrow Aplasia |
11.1% |
| Toxic Optic Neuropathy |
8.9% |
| Pancreatitis Acute |
6.7% |
| Hypertriglyceridaemia |
5.9% |
| Cytolytic Hepatitis |
5.2% |
| Grand Mal Convulsion |
5.2% |
| Rhabdomyolysis |
5.2% |
| Toxic Skin Eruption |
5.2% |
| Hyperbilirubinaemia |
3.7% |
| Thrombocytopenia |
3.7% |
| Bacterial Sepsis |
2.2% |
| Cerebral Venous Thrombosis |
2.2% |
| Encephalopathy |
2.2% |
| Hepatocellular Injury |
2.2% |
| Hypertrophic Cardiomyopathy |
2.2% |
| Leukoencephalopathy |
2.2% |
| Mixed Liver Injury |
2.2% |
| Pancreatitis |
2.2% |
| Pulmonary Embolism |
2.2% |
|
| Concomitant |
| Product Used For Unknown Indication |
28.6% |
| Acute Lymphocytic Leukaemia |
21.4% |
| Drug Use For Unknown Indication |
21.4% |
| Infection Prophylaxis |
14.3% |
| Aspergillosis |
7.1% |
| Pneumocystis Jiroveci Pneumonia |
7.1% |
|
| Drug Interaction |
20.0% |
| Malaise |
20.0% |
| Pyrexia |
20.0% |
| Renal Failure Acute |
20.0% |
| Toxic Skin Eruption |
20.0% |
|
